Prevention and treatment of gerbil hepatitis E using the programmable CRISPR-Cas13d system

作     者：Chengcheng Zhao Chong Lia Sa Li Hanyu Wu Pengyao Ren Tianlong Liu Xiaoxiang Hu Ran Zhang Chengcheng Zhao;Chong Li;Sa Li;Hanyu Wu;Pengyao Ren;Tianlong Liu;Xiaoxiang Hu;Ran Zhang

作者机构：State Key Laboratory of Animal Biotech BreedingCollege of Biological SciencesChina Agricultural UniversityBeijing 100193China Laboratory of Veterinary Pathology and NanopathologyCollege of Veterinary MedicineChina Agricultural UniversityBeijing 100193China 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2024年第11卷第4期

页      面：94-97页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by the National Transgenic Major Program of China(No.2016ZX08009-003-006) Plan 111(No.B12008) 

主　　题：mortality hepatitis treatment 

摘      要：In recent years,the global incidence of hepatitis E virus(HEV)has been rising,leading to increased morbidity and mortality associated with ***13,a CRISPR effector,shows promise as an antiviral agent against singlestranded RNA ***13d,a type VI-D effector,exhibits higher efficiency in suppressing RNA viruses compared to other type VI ***,its in vivo activity against RNA viruses in mammals remains unknown.